OnKure Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing precision medicines that target biologically validated drivers of cancers underserved by available therapies... Show more
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| ARKW | 160.75 | 3.38 | +2.15% |
| ARK Next Generation Technology ETF (ARKW) | |||
| GFGF | 36.30 | 0.30 | +0.83% |
| Guru Favorite Stocks ETF (GFGF) | |||
| KCAI | 32.06 | 0.02 | +0.05% |
| KraneShares China Alpha Index ETF (KCAI) | |||
| EVSB | 50.71 | -0.02 | -0.04% |
| Eaton Vance Ultra-Short Income ETF (EVSB) | |||
| KBA | 29.11 | -0.36 | -1.22% |
| KraneShares Bosera MSCI China A 50 Connect Index ETF (KBA) | |||
A.I.dvisor indicates that over the last year, OKUR has been loosely correlated with MGX. These tickers have moved in lockstep 34% of the time. This A.I.-generated data suggests there is some statistical probability that if OKUR jumps, then MGX could also see price increases.
| Ticker / NAME | Correlation To OKUR | 1D Price Change % | ||
|---|---|---|---|---|
| OKUR | 100% | -2.54% | ||
| MGX - OKUR | 34% Loosely correlated | -0.30% | ||
| KURA - OKUR | 33% Loosely correlated | -1.00% | ||
| SGMT - OKUR | 33% Poorly correlated | +2.57% | ||
| RXRX - OKUR | 33% Poorly correlated | -0.55% | ||
| RCKT - OKUR | 32% Poorly correlated | -5.98% | ||
More | ||||
Industry Biotechnology
The Moving Average Convergence Divergence (MACD) for OKUR turned positive on October 19, 2026. Looking at past instances where OKUR's MACD turned positive, the stock continued to rise in 14 of 16 cases over the following month. The odds of a continued upward trend are 88%.
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where OKUR's RSI Oscillator exited the oversold zone, 7 of 9 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 78%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 18 of 24 cases where OKUR's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 75%.
Following a +12.38% 3-day Advance, the price is estimated to grow further. Considering data from situations where OKUR advanced for three days, in 60 of 76 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.
OKUR may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where OKUR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for OKUR entered a downward trend on October 21, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron PE Growth Rating for this company is 11 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 41 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.541) is normal, around the industry mean (2.988). P/E Ratio (-0.759) is within average values for comparable stocks, (-1.158). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (123.903) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (438.009).
The Tickeron Price Growth Rating for this company is 85 (best 1 - 100 worst), indicating slightly worse than average price growth. OKUR’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. OKUR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.